Last reviewed · How we verify
Doxorubicine + docetaxel sequential
A sequential chemotherapy regimen combining doxorubicin (an anthracycline topoisomerase II inhibitor) followed by docetaxel (a taxane microtubule stabilizer) to maximize cytotoxic effects against cancer cells.
A sequential chemotherapy regimen combining doxorubicin (an anthracycline topoisomerase II inhibitor) followed by docetaxel (a taxane microtubule stabilizer) to maximize cytotoxic effects against cancer cells. Used for Breast cancer (early-stage and metastatic), Potentially other solid tumors in phase 3 evaluation.
At a glance
| Generic name | Doxorubicine + docetaxel sequential |
|---|---|
| Sponsor | Sanofi |
| Drug class | Chemotherapy combination (anthracycline + taxane) |
| Target | Topoisomerase II (doxorubicin); β-tubulin/microtubules (docetaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Doxorubicin intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. Docetaxel stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation. The sequential administration allows each agent to exert its mechanism independently, potentially improving efficacy and tolerability compared to concurrent dosing.
Approved indications
- Breast cancer (early-stage and metastatic)
- Potentially other solid tumors in phase 3 evaluation
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Peripheral neuropathy (docetaxel-related)
- Fatigue
Key clinical trials
- Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer (NA)
- A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (PHASE1)
- Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)
- A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer (PHASE3)
- Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (PHASE3)
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (PHASE3)
- Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (PHASE2)
- Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |